The short version of research peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
=== Portable cordless vacuums === For the Apollo space mission, NASA required a portable, self-contained drill capable of extracting core samples from below the lunar surface. Black & Decker was tasked with the job, and developed a computer program to optimize the design of the drill's motor and ensure minimal power consumption. That computer program led to the development of a cordless miniature vacuum cleaner called the DustBuster.
Tulips are spring-blooming perennial herbaceous bulbiferous geophytes in the Tulipa genus. Their flowers are usually large, showy, and brightly coloured, generally red, orange, pink, yellow, or white. They often have a different coloured blotch at the base of the tepals, internally. Because of a degree of variability within the populations and a long history of cultivation, classification has been complex and controversial. The tulip is a member of the lily family, Liliaceae, along with 14 other genera, where it is most closely related to Amana, Erythronium, and Gagea in the tribe Lilieae. There are about 75 species, and these are divided among four subgenera. The name "tulip" is thought to be derived from a Turkish word for turban, which it may have been thought to resemble by those who discovered it. Tulips were originally found in a band stretching from Southern Europe to Central Asia, but since the seventeenth century have become widely naturalised and cultivated (see map). In their natural state, they are adapted to steppes and mountainous areas with temperate climates. Flowering in the spring, they become dormant in the summer once the flowers and leaves die back, emerging above ground as a shoot from the underground bulb in early spring. Growing wild over much of the Near East and Central Asia, the Persian and Turkish people were the first to cultivate tulips. The cultivation of tulips dates back to 10th-century Persia. Tulips were probably introduced into Anatolia with the advance of the Seljuks.
Former Australian football player Adam Cooney stated, "I would say that 90–95 per cent of the population would put their hand up and do [what James Magnussen did], they're not going to get anywhere near a world record obviously, but it is pretty enticing." Swimmer Kyle Chalmers, who declined joining TEG since he wants to compete in the 2028 Olympics, voiced support for retired swimmers like Magnussen if they wanted to join TEG. He said "I think that swimmers have been underpaid for a very long time at the big competitions."
== Background == A QT interval is a value that is measured on an electrocardiogram. Measurements begin from the start of the Q wave to the end of the T wave. The value is an indication of the time it takes for a ventricle from the beginning of a contraction to the end of relaxation. The value for a normal QT interval is similar in males and females from birth up to adolescence. During infancy, a normal QTc is defined as 400±20 milliseconds. Before puberty, the 99th percentile of QTc values is 460 milliseconds. After puberty, this value increases to 470 milliseconds in males and 480 milliseconds in females. Torsades de pointes (TdP) is an arrhythmia. More specifically, it is one form of a polymorphic ventricular tachycardia that presents with a long QT interval. Diagnosis is made by electrocardiogram (EKG), which shows rapid irregular QRS complexes. The term "torsades de pointes" is translated from French as "twisting of the peaks" because the complexes appear to undulate, or twist around, the EKG baseline. TdP can be acquired by inheritance of a congenital long QT syndrome, or more commonly from the ingestion of a pharmacologic drug. During TdP episodes, patients have a heart rate of 200 to 250 beats/minute, which may present as palpitations or syncope. TdP often self-resolves, however, it may lead to ventricular fibrillation and cause sudden cardiac death.
Sources: en.wikipedia.org
If there have not been out of tolerance temperatures for critical times, continue to use the shipment, without special inspection If potentially damaging temperature hazards have occurred, thoroughly inspect the shipment for damage or degradation. Possibly accelerate sale and use because of reduced shelf life. The consignee may negotiate with the carrier or shipper or even choose to reject a shipment where sensors indicate severe temperature history The time of the temperature extreme, or GPS tracking, may be able to determine the location of the infraction to direct appropriate corrective action. Multiple replicate shipments of data loggers are also used to compare modes of shipment (routes, vendors) and to develop composite data to be used in package testing protocols. There are many brands and models of data loggers. Most are a connectable device that must be plugged into a computer to extract the data that the logger has logged.
=== Cellulose nanofiber plate === A bottom up approach can be used to create a high-performance bulk material with low density, high strength and toughness, and great thermal dimensional stability: cellulose nanofiber plate (CNFP). Cellulose nanofiber hydrogel is created by biosynthesis. The hydrogels can then be treated with a polymer solution or by surface modification and then are hot-pressed at 80 °C. The result is bulk material with excellent machinability. "The ultrafine nanofiber network structure in CNFP results in more extensive hydrogen bonding, the high in-plane orientation, and "three way branching points" of the microfibril networks". This structure gives CNFP its high strength by distributing stress and adding barriers to crack formation and propagation. The weak link in this structure is bond between the pressed layers which can lead to delamination. To reduce delamination, the hydrogel can be treated with silicic acid, which creates strong covalent cross-links between layers during hot pressing.
EC 2.4.2.24: 1,4-β-D-xylan synthase EC 2.4.2.25: flavone apiosyltransferase EC 2.4.2.26: protein xylosyltransferase EC 2.4.2.27: dTDP-dihydrostreptose—streptidine-6-phosphate dihydrostreptosyltransferase EC 2.4.2.28: S-methyl-5′-thioadenosine phosphorylase EC 2.4.2.29: tRNA-guanosine34 preQ1 transglycosylase EC 2.4.2.30: NAD+ ADP-ribosyltransferase EC 2.4.2.31: NAD+—protein-arginine ADP-ribosyltransferase EC 2.4.2.32: dolichyl-phosphate D-xylosyltransferase EC 2.4.2.33: dolichyl-xylosyl-phosphate—protein xylosyltransferase EC 2.4.2.34: indolylacetylinositol arabinosyltransferase EC 2.4.2.35: flavonol-3-O-glycoside xylosyltransferase EC 2.4.2.36: NAD+—diphthamide ADP-ribosyltransferase EC 2.4.2.37: NAD+ —dinitrogen-reductase ADP-D-ribosyltransferase EC 2.4.2.38: glycoprotein 2-β-D-xylosyltransferase EC 2.4.2.39: xyloglucan 6-xylosyltransferase EC 2.4.2.40: zeatin O-β-D-xylosyltransferase EC 2.4.2.41: xylogalacturonan β-1,3-xylosyltransferase EC 2.4.2.42: UDP-D-xylose:β-D-glucoside α-1,3-D-xylosyltransferase EC 2.4.2.43: lipid IVA 4-amino-4-deoxy-L-arabinosyltransferase EC 2.4.2.44: S-methyl-5′-thioinosine phosphorylase EC 2.4.2.45: decaprenyl-phosphate phosphoribosyltransferase EC 2.4.2.46: galactan 5-O-arabinofuranosyltransferase EC 2.4.2.47: arabinofuranan 3-O-arabinosyltransferase EC 2.4.2.48: tRNA-guanine15 transglycosylase EC 2.4.2.49: neamine phosphoribosyltransferase EC 2.4.2.50: cyanidin 3-O-galactoside 2′′-O-xylosyltransferase EC 2.4.2.51: anthocyanidin 3-O-glucoside 2′′′-O-xylosyltransferase EC 2.4.2.52: triphosphoribosyl-dephospho-CoA synthase EC 2.4.2.53: undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase EC 2.4.2.54: β-ribofuranosylphenol 5′-phosphate synthase EC 2.4.2.55: nicotinate D-ribonucleotide:phenol phospho-D-ribosyltransferase EC 2.4.2.56: kaempferol 3-O-xylosyltransferase EC 2.4.2.57: AMP phosphorylase EC 2.4.2.58: hydroxyproline O-arabinosyltransferase EC 2.4.2.59: sulfide-dependent adenosine diphosphate thiazole synthase EC 2.4.2.60: cysteine-dependent adenosine diphosphate thiazole synthase EC 2.4.2.61: α-dystroglycan β1,4-xylosyltransferase EC 2.4.2.62: xylosyl α-1,3-xylosyltransferase EC 2.4.2.63: EGF-domain serine xylosyltransferase EC 2.4.2.64: tRNA-guanosine34 queuine transglycosylase
When asked at trial why she had not spoken against the ongoing physical, emotional, and sexual abuse she had endured for seven years before running away from home when she was aged 15, Anna Marie emphasised that, as a child and adolescent, she had not known any other normality, adding, "[My father and stepmother] were all I had." Fred's younger brother, John, hanged himself in the garage of his Gloucester home in November 1996. At the time of his suicide, he had been awaiting the jury verdict in his trial for the alleged multiple rapes of his niece, Anna Marie, and another underage girl at Cromwell Street in the 1970s. The Wests' son Stephen is also known to have made a suicide attempt by hanging in 2002. In 2004 he was jailed for nine months for having unlawful sex with a 14-year-old girl on multiple occasions. Another of the West children, Barry, took his own life via a suspected drug overdose in October 2020 at the age of 40. For several years prior to his death, he is known to have battled a drug addiction and psychiatric problems as a result of the abuse he had endured and witnessed, including the murder of his sister Heather, as a child. The Wests' house in Cromwell Street was demolished in October 1996, with every piece of debris destroyed to discourage potential souvenir hunters. It had been referred to in the press as the "House of Horrors." The site was later redeveloped into a public pathway. As of May 2026, Rose remains incarcerated at New Hall jail, in Wakefield, West Yorkshire, where she maintains her innocence.
== Further reading == Ordoñez-Araque, Roberto; Quishpillo-Miranda, Nadine; Ramos-Guerrero, Luis (2022). "Edible Insects for Humans and Animals: Nutritional Composition and an Option for Mitigating Environmental Damage". Insects. 13 (10): 944. doi:10.3390/insects13100944. PMC 9604210. PMID 36292894. Lange, Klaus W.; Nakamura, Yukiko (2023). "Potential contribution of edible insects to sustainable consumption and production". Frontiers in Sustainability. 4 1112950. Bibcode:2023FrSus...412950L. doi:10.3389/frsus.2023.1112950. Baiano, Antonietta (2020). "Edible insects: An overview on nutritional characteristics, safety, farming, production technologies, regulatory framework, and socio-economic and ethical implications". Trends in Food Science and Technology. 100: 35–50. doi:10.1016/j.tifs.2020.03.040. Ordoñez-Araque, Roberto; Egas-Montenegro, Erika (2021). "Edible insects: A food alternative for the sustainable development of the planet". International Journal of Gastronomy and Food Science. 23 100304. doi:10.1016/j.ijgfs.2021.100304. Li, Mengjiao; Mao, Chengjuan; Li, Xin; Jiang, Lei; Zhang, Wen; Li, Mengying; Liu, Huixue; Fang, Yaowei; Liu, Shu; Yang, Guang; Hou, Xiaoyue (2023). "Edible Insects: A New Sustainable Nutritional Resource Worth Promoting". Foods. 12 (22): 4073. doi:10.3390/foods12224073. PMC 10670618. PMID 38002131. Tang, Chufei; Yang, Ding; Liao, Huaijian; Sun, Hongwu; Liu, Chuanjing; Wei, Lanjun; Li, Fanfan (2019). "Edible insects as a food source: a review". Food Production, Processing and Nutrition. 1 8. doi:10.1186/s43014-019-0008-1.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.